Clinical Trials Directory

Trials / Recruiting

RecruitingNCT06916884

Confirmatory Study on the Efficacy and Safety of the Fixed-dose Combination of Desloratadine/Betamethasone Versus Desloratadine

Confirmatory Study on the Efficacy and Safety of the Fixed-dose Combination of Desloratadine/Betamethasone Versus Desloratadine as Treatment in Patients With Allergic Rhinitis

Status
Recruiting
Phase
Phase 3
Study type
Interventional
Enrollment
70 (estimated)
Sponsor
Laboratorios Silanes S.A. de C.V. · Industry
Sex
All
Age
18 Years – 60 Years
Healthy volunteers
Not accepted

Summary

Phase IIIb , longitudinal, multicenter, randomized, double-blind, to evaluate efficacy and safety of the fixed-dose combination of Desloratadine 5 mg / Betamethasone 0.25 mg versus Desloratadine 5 mg monotherapy as treatment for symptoms associated with allergic rhinitis.

Detailed description

Nasal symptom changes will be assessed daily over a 10-day intervention period using the Total Nasal Symptom Score (TNSS) for allergic rhinitis. Patients will complete the first questionnaire during the randomization visit, followed by daily entries each night before bedtime using a patient diary. The final assessment will be completed during the study's end-of-treatment visit. Quality of life, global clinical impression, and patient global assessment will be evaluated during in-person visits conducted at baseline, Day 5, and Day 10. The incidence of adverse events throughout the study will be analyzed by treatment group and reported as frequencies and percentages. Events will be classified according to frequency, seriousness, severity, and their relationship to the investigational product.

Conditions

Interventions

TypeNameDescription
DRUGDesloratadine / Betamethasone in fixed dose1 tablet, once a day of 5 mg / 0.25 mg
DRUGDesloratadine1 tablet, once a day of 5 mg

Timeline

Start date
2024-11-11
Primary completion
2025-05-11
Completion
2025-06-11
First posted
2025-04-08
Last updated
2025-04-08

Locations

1 site across 1 country: Mexico

Source: ClinicalTrials.gov record NCT06916884. Inclusion in this directory is not an endorsement.